

HEMATOLOGY, TRANSFUSION AND CELL THERAPY




www.htct.com.br

Images in Clinical Hematology

VEXAS syndrome: more than just vacuoles



Marco P. Barros Pinto • *



ARTICLE INFO

Article history:
Received 22 May 2025
Accepted 8 June 2025
Available online 16 September 2025

A 78-year-old man with an autoimmune disorder (vasculitis) and a recent diagnosis of VEXAS syndrome, confirmed by next generation sequencing (presence of the p.Met41Thr variant of the UBA1 gene with a variant allele frequency of 56.4 %) was admitted to hospital.

Analytically he presented: erythrocytes $3.75 \times 10^{12}/L$ (reference values [RV]: $4.5-5.9 \times 10^{12}/L$), hemoglobin 132 g/L (RV: 130–175 g/L), mean corpuscular volume 103.6 fL (RV: 80–97 fL), leucocytes $3.9 \times 10^9/L$ (69 % neutrophils, 20 % lymphocytes), and platelets $197 \times 10^9/L$ (RV: $150-450 \times 10^9/L$).

The bone marrow aspirate smears were normocellular, with a myeloid to erythroid (M:E) ratio of 2:1. The smears also revealed 20 % myeloid precursors (all stages) and 30 % proerythroblasts with cytoplasmic vacuoles. Other notable findings included pseudo-Pelger-Hüet anomalies and megaloblastic precursors. Most of the megakaryocytes exhibited a high nuclear-to-cytoplasmic ratio; specifically, 50 % of total megakaryocytes (TM) were monolobated with eccentrically placed nuclei, and other megakaryocytes showed a wreath-like rearrangement of nuclear lobes. Additionally, multinuclear megakaryocytes (3 % TM) and megakaryocyte emperipolesis (3 % TM) were observed (Figure 1). There was no increase in blasts. Storage iron was decreased with no ring sideroblasts.

E-mail address: marco.pinto@chln.min-saude.pt https://doi.org/10.1016/j.htct.2025.103984

VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoin-flammatory, somatic) was first reported by Beck et al. in 2020. Vacuoles are observed in erythroid and myeloid precursor cells [1]. The E1 enzyme is related to the ubiquitin activating enzyme encoded by the UBA1 gene, an X-linked gene [1]. Mutation in this gene is responsible for an autoinflammatory disease (characterized by recurrent fevers, cytopenias, chondritis, vasculitis, pulmonary inflammation, and neutrophilic dermatoses) as the result of somatic mutations in the blood [1].

The most frequent mutations are p.Met41Thr (49 %), p. Met41Val (26 %) and p.Met41Leu (19 %) [2].

In VEXAS syndrome the bone marrow is usually hypercellular with an increased M:E ratio (>4:1 in >70 % of cases) [2]. The presence of ≥10 % of myeloid precursors with >1 vacuole can be both sensitive and specific for VEXAS syndrome, [3] however cytoplasmic vacuolization of myeloid and erythroid precursors can be found in other clinical settings: alcohol abuse, copper deficiency, treatments (chemotherapy and antibiotics), zinc toxicity, myelodysplastic syndrome, lymphoproliferative disorders, multiple myeloma, myeloproliferative neoplasms and acute myeloid leukemia, or as an artifact of sample preparation [2,3]. Furthermore, some atypical UBA1 variants can present absence of precursor vacuolization in the bone marrow [2].

Storage iron is usually increased with no significant number of ring sideroblasts (<10 % of cases) [2].

^{*} Correspondence author at: Centro Hospitalar Universitário Lisboa Norte, EPE, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal.




Figure 1–Bone marrow aspirate (May-Grünwald-Giemsa stain, \times 100 objective): Myeloid precursors with vacuoles (A, B); proerythroblasts with vacuoles (C, D); megaloblastic precursors (D, E, F); pseudo-Pelger-Hüet (G); monolobated megakaryocytes (H); megakaryocytes with a wreath-like rearrangement of nuclear lobes (I, J); megakaryocytes emperipolesis (K, L).

The full blood count can show: macrocytic anemia (90 –100 %), lymphopenia (60–80 %), monocytopenia (50 %), neutropenia (<30 %) and thrombocytopenia (45–69 %) [2].

The UBA1 gene mutation is also a predisposing factor for myelodysplastic syndromes, plasma cell proliferation disorders (monoclonal gammopathy of undetermined significance, multiple myeloma) or both [2].

Conflicts of interest

The author declares no conflicts of interest.

REFERENCES

- [1]. Grayson PC, Patel BA, Young NS. VEXAS syndrome. Blood. 2021;137(26):3591-4. https://doi.org/10.1182/blood.2021011455.
- [2]. Koster MJ, Lasho TL, Olteanu H, et al. VEXAS syndrome: clinical, hematologic features and a practical approach to diagnosis and management. Am J Hematol. 2024;99(2):284–99. https://doi.org/10.1002/ajh.27156.
- [3]. Cherniawsky H, Friedmann J, Nicolson H, et al. VEXAS syndrome: a review of bone marrow aspirate and biopsies reporting myeloid and erythroid precursor vacuolation. Eur J Haematol. 2023;110(6):633–8. https://doi.org/10.1111/ejh.13944.